New shot could help teens with severe eczema
NCT ID NCT06277765
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The drug is a lab-made antibody that blocks a key protein involved in inflammation. The goal was to see if it improves skin clearing and reduces itch compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM310 (a monoclonal antibody that blocks interleukin-4 receptor alpha)
- What this could lead to
- If successful, this could provide a new treatment option for adolescents with moderate-to-severe eczema, helping to clear skin and reduce itch.
- What could go wrong
- This is a single phase 3 trial with 180 participants. Results may not apply to all patients, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?